

Tezspire[®] (teplizumab-ekko) – New dosage formulation

- On February 2, 2023, [AstraZeneca and Amgen announced](#) the [FDA approval](#) of [Tezspire \(teplizumab-ekko\)](#) solution in a single-dose pre-filled pen.
 - Tezspire pre-filled pen **can be administered by patients/caregivers** or healthcare providers.
 - Patients/caregivers may administer Tezspire pre-filled pen after proper training in subcutaneous (SC) injection technique and after the healthcare provider determines it is appropriate.
- Tezspire is also approved as a solution in a single-dose vial and as a single-dose pre-filled syringe, but both are intended for administration by a healthcare provider.
- Tezspire is approved for add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
- The recommended dosage of Tezspire is 210 mg administered SC once every 4 weeks.
- Amgen and AstraZeneca's launch plans for Tezspire prefilled pen are pending. The prefilled pen will be available as a 210 mg/1.91 mL dose.